01 Adoption of Digital PCR for High-Sensitivity Testing The in vitro diagnostics market analysis shows that the need for precise detection of low-abundance genetic material encourages diagnostic manufacturers to adopt digital polymerase chain reaction (dPCR) technologies. Digital PCR platforms divide samples into thousands of individual reactions, enabling absolute nucleic acid quantification and improved detection of rare genetic variants.
02 Development of Multi-Omics Diagnostic Platforms The complexity of diseases such as cancer and neurological disorders encourages diagnostic developers to combine multiple molecular data types for more comprehensive disease analysis. Multi-omics platforms integrate genomic, transcriptomic, proteomic, and metabolomic information to identify disease-associated biomarkers and improve molecular profiling.
01 Stringent Regulatory Approval Requirements and Limited Reimbursement for Diagnostic Tests Restrain Market Expansion Stringent regulatory approval requirements increase compliance costs and extend product development timelines for in vitro diagnostic manufacturers. Extensive clinical validation, performance testing, and documentation requirements delay product approvals and increase financial pressure on smaller companies. Limited insurance coverage and inadequate reimbursement policies increase out-of-pocket expenses for patients requiring diagnostic testing. Low reimbursement rates reduce healthcare providers' profitability and discourage laboratories from offering certain specialized and advanced diagnostic tests.
01 Preference for Non-Invasive Prenatal Testing Services and Home-Based Fertility and Hormone Testing Offers Growth Opportunities Non-invasive prenatal testing provides diagnostic manufacturers and genetic testing laboratories with opportunities to expand specialized maternal healthcare services. Maternal blood-based screening for fetal chromosomal abnormalities supports partnerships with maternity hospitals, obstetric clinics, and genetic counseling centers. Consumer interest in reproductive health monitoring opens new commercial avenues for diagnostic device manufacturers and digital health companies. Home-based fertility testing solutions enable individuals to track hormone levels, identify fertile windows, and monitor ovulation patterns without frequent laboratory visits.
September 2026 – Abbott announced the launch of its SimpleScreen CRC blood test, expanding its colorectal cancer screening portfolio alongside Cologuard Plus.
September 2026 – Roche announced that the U.S. FDA approved expanded use of its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail tests.
August 2026 – QIAGEN received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, which detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in approximately one hour.
April 2026 – QuidelOrtho completed its acquisition of LEX Diagnostics for approximately USD 100 million, strengthening its presence in rapid molecular point-of-care testing. The acquisition adds the LEX VELO System, an FDA-cleared and CLIA-waived platform capable of detecting influenza A, influenza B, and COVID-19 in approximately 6–10 minutes.